

Laura Zannini

- Dati personali:** Luogo e data di nascita: Milano, 27/09/1974
Cittadinanza: Italiana
- Educazione:** Dicembre 2013 **Abilitazione alla professione di biologo**
Luglio 2007 **PhD** presso la Open University, Milton Keynes, UK. Studi svolti presso: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.
Maggio 1999 **Laurea in Scienze Biologiche** presso l'Università degli Studi di Milano. Mark: 110/110
- Esperienza lavorativa:** Dicembre 2016-oggi: **Ricercatore** presso **Istituto di Genetica Molecolare Luigi Luca Cavalli-Sforza, Consiglio Nazionale delle Ricerche (IGM-CNR)**, Pavia
Giugno 1999-December 2016: **PhD student, Post-Doc and PI** presso **Fondazione IRCCS Istituto Nazionale dei Tumori** (Milano).
Gennaio-Marzo 2001: **PhD student** presso **Laboratorio Nazionale C.I.B.** (Area Science Park, Padriciano, Trieste)
- Esperienze da revisore:** Revisore di pubblicazioni scientifiche per diverse riviste internazionali come: Cellular Physiology and Biochemistry, Neoplasia, BMC geriatrics, BMC cancer, Carcinogenesis, Cancer Biology and Therapy, FEBS Open Bio, Cancer Science, Nature Communications, Communications Biology, Cell Death & Disease, iScience.
- Esperienza di docenza:** Ottobre 2023-oggi: Professore a contratto per l'insegnamento del corso di Biologia Molecolare II presso l'Università di Pavia, corso di laurea triennale in Scienze Biologiche.
- Pubblicazioni:** Livraghi et al. A proteasome-dependent inhibition of SIRT-1 by the resveratrol analogue 4,4'-dihydroxy-trans-stilbene. **J. of traditional and complementary medicine**. E-pub ahead of print (2024)

Celli L, ... **Zannini L.*** and Cardano M.* CRISPR/Cas9 mediated Y-chromosome elimination affects human cells transcriptome. **Cell & Biosci.** 14(1):15 (2024)

Cardano M,... and **Zannini L.** Sex specific regulation of TSPY-Like 2 in the DNA damage response of cancer cells. **Cell Death & Dis.** 14(3): 197 (2023)

Cardano M,... and **Zannini L.** Sex disparities in DNA damage response pathways: Novel determinants in cancer formation and therapy. **iSCIENCE.** 25 (3): 103875 (2022)

*Magni M.,... and **Zannini L.*** TSPYL2 is a novel regulator of SIRT1 and p300 activity in response to DNA damage. **Cell Death and Differentiation.** 26(5):918-931 (2019)

*Magni M., Buscemi., **Zannini L.*** Cell cycle and apoptosis regulator 2 at the interface between DNA damage response and cell physiology. **Mutation research-Reviews in mutation research.** 776:1-9 (2018)

*Restelli M.,... and **Zannini L.*** A novel crosstalk between CCAR2 and AKT pathway in the regulation of cancer cell proliferation. **Cell Death & Disease** 7(11):e2453. doi: 10.1038/cddis.2016.359 (2016)

*Magni M.,... and **Zannini L.*** CCAR2/DBC1 is required for Chk2-dependent KAP1 phosphorylation and repair of DNA damage. **Oncotarget,** 6, 17817-31 (2015)

*Magni M.,... and **Zannini L.*** Chk2 and REGγ-dependent DBC1 regulation in DNA damage induced apoptosis. **Nucleic Acids Res.,** 42, 13150-13160 (2014)

Zannini L., et al. Chk2 kinase in the DNA damage response and beyond. **J. Mol. Cell Biol.,** 6: 442-457 (2014)

Buscemi G., et al. Bimodal regulation of p21^{waf1} protein as function of DNA damage levels. **Cell Cycle,** 13: 2901-2912 (2014)

Zannini L., et al. DBC1 phosphorylation by ATM/ATR inhibits SIRT1 deacetylase in response to DNA damage. **J. Mol. Cell Biol.**, 4: 294-303 (2012).

Turinetto V, et al. A novel defect in mitochondrial p53 accumulation following DNA damage confers apoptosis resistance in Ataxia Telangiectasia and Nijmegen Breakage Syndrome T-cells. **DNA Repair**, 9:1200-1208 (2010).

Zannini L., et al. REGgamma/PA28gamma proteasome activator interacts with PML and Chk2 and affects PML nuclear bodies number. **Cell Cycle**. 8:2399-407 (2009).

Buscemi G., et al. The shelterin protein TRF2 inhibits Chk2 activity at telomeres in the absence of DNA damage. **Curr. Biol.** 19:874-9 (2009)

Zannini L., et al. REG γ proteasome activator is involved in the maintenance of chromosomal stability. **Cell Cycle**, 7:504-12 (2008).

Bruno T., et al. Che-1 phosphorylation by ATM/ATR and Chk2 kinases activates p53 transcription and the G2/M checkpoint. **Cancer Cell**, 10:473-86 (2006).

Buscemi G., et al. DNA damage-induced cell cycle regulation and function of novel Chk2 phosphoresidues. **Mol. Cell. Biol.**, 26:7832-45 (2006).

Caramuta S., et al. Regulation of lipocalin-2 gene by the cancer chemopreventive retinoid 4-HPR. **Int. J. Cancer**, 119:1599-606 (2006).

Zannini L., et al. Karyopherin-alpha2 protein interacts with Chk2 and contributes to its nuclear import. **J. Biol. Chem.**, 278: 42346-51 (2003).

Oguchi K., et al. Missense mutation and defective function of ATM in a childhood acute leukemia patient with MLL gene rearrangement. **Blood**, 101: 3622-7 (2003).

Buscemi G, et al. Chk2 activation dependence on Nbs1 after DNA damage. **Mol. Cell. Biol.** 21(15): 5214-22 (2001)

Biunno I, et al. SEL1L, the human homolog of *C. elegans* sel-1: refined physical mapping, gene structure and identification of polymorphic markers. **Hum. Genet.** 106:227-35 (2000)

Capitoli di libri: Zannini L., *Buscemi G.* “CHK2” per **Encyclopedia of Signaling Molecules, 2nd Edition (Springer Nature)**. Responsabile editoriale Prof. Sangdun Choi.

Acconsento al trattamento dei dati personali ai sensi dell'art. 13 del D. Lgs. 196/2013 e dell'art. 13 GDPR 679/2016